Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vildagliptin
Drug ID BADD_D02357
Description Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired.[A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote insulin secretion and regulate blood glucose levels. Elevated levels of GLP-1 and GIP consequently results in improved glycemic control.[L32803] In clinical trials, vildagliptin has a relatively low risk of hypoglycemia.[A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea, or a thiazolidinedione in patients with inadequate glycemic control following monotherapy. It is marketed as Galvus.[L32803] Vildagliptin is also available as Eucreas, a fixed-dose formulation with metformin for adults in who do not adequately glycemic control from monotherapy.[L32813] Vildagliptin is currently under investigation in the US.
Indications and Usage Used to reduce hyperglycemia in type 2 diabetes mellitus.
Marketing Status Not Available
ATC Code A10BH02
DrugBank ID DB04876
KEGG ID D07080
MeSH ID D000077597
PubChem ID 5251896
TTD Drug ID D0L3DK
NDC Product Code 50370-0032; 65372-1200; 69037-0028; 66651-102; 65727-051
Synonyms Vildagliptin | (2S)-(((3-Hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile | NVP-LAF237 | NVP LAF237 | Galvus
Chemical Information
Molecular Formula C17H25N3O2
CAS Registry Number 274901-16-5
SMILES C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.001--
Weight increased13.15.01.006--
Musculoskeletal discomfort15.03.04.001--Not Available
Angiopathy24.03.02.007--Not Available
Connective tissue disorder15.06.01.006--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Hepatobiliary disease09.01.08.003--Not Available
The 2th Page    First    Pre   2    Total 2 Pages